US · SI · MEDICAL - SPECIALTIES
Shoulder Innovations, Inc. (SI) intrinsic value and stock valuation
$20.15as of 2026-11-21 · Mkt cap 427M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Shoulder Innovations, Inc. DCF and intrinsic value
InvestorsCraft values SI with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from SI’s statements →
Shoulder Innovations, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2023–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Assembly Biosciences, Inc. (ASMB) $22.19
- Enanta Pharmaceuticals, Inc. (ENTA) $7.62
- Eupraxia Pharmaceuticals Inc. (EPRX) $5.80
- Inogen, Inc. (INGN) $5.30
- Aardvark Therapeutics, Inc. Common Stock (AARD) $0.92
- Nautilus Biotechnolgy, Inc. (NAUT) $2.12
- Outset Medical, Inc. (OM) $2.81
- Nano-X Imaging Ltd. (NNOX) $0.23
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $47.3M | $31.6M | $19.3M |
| Operating income | -$-26.3M | -$-14.65M | -$-10.86M |
| Net income | -$-40.36M | -$-15.62M | -$-12.65M |
| EPSd | -$-1.96M | -$-784.14K | -$-635.04K |
| Operating cash flow | -$-28.61M | -$-14.14M | -$-13.14M |
| Capital expenditure | -$-7.41M | -$-4.01M | -$-2.75M |
| Free cash flow | -$-36.02M | -$-18.16M | -$-15.89M |
| Total assets | $169.9M | $43.1M | $54.3M |
| Total debt | $15M | $14.7M | $14.5M |
| Net debt | -$-11.85M | $8.61M | $8.23M |
| Total equity | $154.9M | -$-54.7M | -$-39.74M |
| Cash and short-term investments | $124.3M | $15M | $32.8M |
Income statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $47.3M | $31.6M | $19.3M |
| Cost of revenue | $11.1M | $7.28M | $4M |
| Gross profit | $36.2M | $24.3M | $15.3M |
| Research and development expenses | $7.73M | $4.49M | $3.02M |
| Selling, general and administrative expenses | $54.8M | $34.5M | $23.1M |
| Other expenses | $0.00 | $0.00 | $0.00 |
| Operating expenses | $62.5M | $39M | $26.1M |
| Cost and expenses | $73.6M | $46.3M | $30.1M |
| Interest income | $0.00 | $0.00 | $0.00 |
| Interest expense | $70K | $1.32M | $760K |
| Depreciation and amortization | $3.21M | $2.2M | $1.64M |
| Ebitda | -$-37.08M | -$-12.11M | -$-10.25M |
| Operating income | -$-26.3M | -$-14.65M | -$-10.86M |
| Total other income/expenses, net | -$-14.06M | -$-970K | -$-1.79M |
| Income before tax | -$-40.36M | -$-15.62M | -$-12.65M |
| Income tax expense | $0.00 | $0.00 | $0.00 |
| Net income | -$-40.36M | -$-15.62M | -$-12.65M |
| Weighted average shares outstanding | $20.6M | $19.9M | $19.9M |
| Weighted average diluted shares outstanding | $20.6M | $19.9M | $19.9M |
Balance sheet
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Cash and short-term investments | $124.3M | $15M | $32.8M |
| Net receivables | $8.27M | $5.12M | $4.69M |
| Inventory | $21.6M | $14M | $9.92M |
| Total current assets | $157.2M | $35.1M | $47.9M |
| Property, plant and equipment, net | $12.6M | $7.55M | $5.75M |
| Goodwill and intangible assets | $100K | $400K | $700K |
| Long-term investments | $0.00 | $0.00 | $0.00 |
| Total non-current assets | $12.7M | $7.96M | $6.45M |
| Total assets | $169.9M | $43.1M | $54.3M |
| Accounts payable | $0.00 | $4.86M | $1.96M |
| Short-term debt | $60K | $90K | $90K |
| Deferred revenue | $0.00 | $0.00 | $0.00 |
| Total current liabilities | -$-7.77M | $7.65M | $4.28M |
| Long-term debt | $15M | $14.7M | $14.4M |
| Deferred revenue, non-current | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $15M | $90.1M | $89.8M |
| Capital lease obligations | $0.00 | $70K | $110K |
| Total liabilities | $15M | $97.8M | $94M |
| Common stock | $20.6B | $0.00 | $0.00 |
| Retained earnings | $0.00 | -$-57.04M | -$-41.42M |
| Accumulated other comprehensive income (loss) | $0.00 | $200K | $360K |
| Total equity | $154.9M | -$-54.7M | -$-39.74M |
| Total investments | $80K | $8.92M | $26.6M |
| Total debt | $15M | $14.7M | $14.5M |
| Net debt | -$-11.85M | $8.61M | $8.23M |
Cash flow statement
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Net income | -$-40.36M | -$-15.62M | -$-12.65M |
| Depreciation and amortization | $3.21M | $2.2M | $1.64M |
| Stock-based compensation | $1M | $750K | $450K |
| Change in working capital | -$-6.75M | -$-1.04M | -$-4.76M |
| Accounts receivable | -$-3.3M | -$-570K | -$-2.69M |
| Inventory | -$-7.64M | -$-4.03M | -$-2.41M |
| Accounts payable | $3.37M | $3.12M | -$-740K |
| Net cash provided by operating activities | -$-28.61M | -$-14.14M | -$-13.14M |
| Investments in property, plant and equipment | -$-7.41M | -$-4.01M | -$-2.75M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-95.6M | $14M | -$-28.97M |
| Common stock issued | $39.5M | $70K | $34.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $145M | $70K | $44.7M |
| Net change in cash | $20.8M | -$-110K | $2.61M |
| Cash at end of period | $26.9M | $6.12M | $6.24M |
| Operating cash flow | -$-28.61M | -$-14.14M | -$-13.14M |
| Capital expenditure | -$-7.41M | -$-4.01M | -$-2.75M |
| Free cash flow | -$-36.02M | -$-18.16M | -$-15.89M |
Line items
Line items
Line items
About Shoulder Innovations, Inc.
Shoulder Innovations, Inc. manufactures medical devices. It has developed a shoulder replacement system. The company was founded by Stephen B. Gunther and Michael DeVries in 2009 and is headquartered in Grand Rapids, MI.
- CEO
- Robert Joseph Ball
- Employees
- 75
- Beta
- -1.70
Explore
Frequently asked questions
What is the intrinsic value of Shoulder Innovations, Inc. (SI)?
Shoulder Innovations, Inc. (SI) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SI undervalued?
SI trades at a price of $20.15 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.